Frazier Management LLC
- SEC CIK
- 0001032165
- Latest filing
- Nov 14, 2022
Holdings in Q2 2021
Holdings as of Jun 30, 2021, filed Aug 11, 2021. Long positions only; changes compare share counts with Q1 2021.
- Positions
- 34
- −1 vs. Q1 2021
- Portfolio value
- $1.08B
- −$162.5M (−13.0%) vs. Q1 2021
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| ARQTArcutis Biotherapeutics, Inc. | COM | 8,434,232 | $230.2M | 21.2% | −2,108,558−20.0% | Reduced | History |
| PHATPhathom Pharmaceuticals, Inc. | COM | 5,827,415 | $197.3M | 18.2% | 00.0% | Unchanged | History |
| PASGPassage BIO, Inc. | COM | 5,009,219 | $66.3M | 6.1% | 00.0% | Unchanged | History |
| MIRMMirum Pharmaceuticals, Inc. | COM | 3,566,912 | $61.7M | 5.7% | 00.0% | Unchanged | History |
| Translate Bio, Inc.89374L104 | COM | 2,082,789 | $57.4M | 5.3% | −100,000−4.6% | Reduced | – |
| IOVAIovance Biotherapeutics, Inc. | COM | 2,137,999 | $55.6M | 5.1% | +825,000+62.8% | Added | History |
| KRYSKrystal Biotech, Inc. | COM | 787,876 | $53.6M | 4.9% | −107,124−12.0% | Reduced | History |
| PCVXVaxcyte, Inc. | COM | 2,309,554 | $52.0M | 4.8% | 00.0% | Unchanged | History |
| TARSTarsus Pharmaceuticals, Inc. | COM | 1,417,157 | $41.1M | 3.8% | −500,000−26.1% | Reduced | History |
| Trillium Therapeutics Inc.89620X506 | COM NEW | 3,123,107 | $30.3M | 2.8% | 00.0% | Unchanged | – |
| ANABAnaptysbio, Inc | COM | 899,700 | $23.3M | 2.2% | 00.0% | Unchanged | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 2,571,450 | $23.1M | 2.1% | 00.0% | Unchanged | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 1,188,135 | $20.4M | 1.9% | −246,910−17.2% | Reduced | History |
| STROSutro Biopharma, Inc. | COM | 1,001,421 | $18.6M | 1.7% | 00.0% | Unchanged | History |
| ISEEIVERIC bio, Inc. | COM | 2,544,500 | $16.1M | 1.5% | 00.0% | Unchanged | History |
| KDNYChinook Therapeutics, Inc. | COM | 1,100,000 | $15.5M | 1.4% | +1,100,000 | New | History |
| AUTLAutolus Therapeutics plc | SPON ADS | 2,283,966 | $15.2M | 1.4% | +2,283,966 | New | History |
| Frazier Lifesciences Acqu CoG3710A121 | UNIT 12/09/2025 | 1,501,000 | $15.1M | 1.4% | 00.0% | Unchanged | – |
| RGNXREGENXBIO Inc. | COM | 351,954 | $13.7M | 1.3% | 00.0% | Unchanged | History |
| MTEMMolecular Templates, Inc. | COM | 1,374,047 | $10.7M | 1.0% | 00.0% | Unchanged | History |
| GRTSGritstone bio, Inc. | COM | 1,030,878 | $9.41M | 0.9% | 00.0% | Unchanged | History |
| EPIXESSA Pharma Inc. | COM NEW | 316,616 | $9.05M | 0.8% | 00.0% | Unchanged | History |
| ACRSAclaris Therapeutics, Inc. | COM | 370,733 | $6.51M | 0.6% | −325,267−46.7% | Reduced | History |
| EPZMEpizyme, Inc. | COM | 739,369 | $6.14M | 0.6% | 00.0% | Unchanged | History |
| APTXAptinyx Inc. | COM | 1,883,244 | $5.33M | 0.5% | −1,306,835−41.0% | Reduced | History |
| SRRKScholar Rock Holding Corp | COM | 156,000 | $4.51M | 0.4% | 00.0% | Unchanged | History |
| Freeline Therapeutics Hldgs35655L107 | SPONSORED ADS | 550,000 | $4.48M | 0.4% | 00.0% | Unchanged | – |
| ALNAAllena Pharmaceuticals, Inc. | COM | 3,330,373 | $4.33M | 0.4% | 00.0% | Unchanged | History |
| Bellus Health Inc New07987C204 | COM NEW | 1,296,743 | $4.03M | 0.4% | 00.0% | Unchanged | – |
| SRRASierra Oncology, Inc. | COM NEW | 202,803 | $3.95M | 0.4% | 00.0% | Unchanged | History |
| AVDLAvadel Pharmaceuticals PLC | SPONSORED ADR | 578,104 | $3.89M | 0.4% | 00.0% | Unchanged | History |
| IMVTImmunovant, Inc. | COM | 254,000 | $2.69M | 0.2% | −254,000−50.0% | Reduced | History |
| GRTXGalera Therapeutics, Inc. | COM | 241,000 | $2.37M | 0.2% | 00.0% | Unchanged | History |
| Nabriva Therapeutics plcG63637113 | SHS | 425,650 | $575.0K | 0.1% | 00.0% | Unchanged | – |
Sold out since Q1 2021 (3)
Positions held at the end of Q1 2021 that are gone from this filing.
| Security | Class | Shares in Q1 2021 | Value in Q1 2021 | % of portfolio in Q1 2021 | History |
|---|---|---|---|---|---|
| ADVMAdverum Biotechnologies, Inc. | COM | 1,437,028 | $14.2M | 1.1% | History |
| CRDFCardiff Oncology, Inc. | COM | 293,500 | $2.72M | 0.2% | History |
| ITRMIterum Therapeutics plc | SHS | 1,538,316 | $2.17M | 0.2% | History |